Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) (NCT02568267)

🧪 Interventions in This Study

• Entrectinib (DRUG)

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

1. Histologically- or cytologically-confirmed diagnosis of locally advanced or metastatic solid tumor that harbors an NTRK1/2/3, ROS1, or ALK gene rearrangement
2. For patients enrolled via local molecular testing, an archival or fresh tumor tissue (unless medically contraindicated) is required to be submitted for independent central molecular testing at Ignyta's CLIA laboratory post-enrollment
3. Measurable or evaluable disease
4. Patients with CNS involvement, including leptomeningeal carcinomatosis, which is either asymptomatic or previously-treated and controlled, are allowed
5. Prior anticancer therapy is allowed (excluding approved or investigational Trk, ROS1, or ALK inhibitors in patients who have tumors that harbor those respective gene rearrangements) \- Note: prior treatment with crizotinib is permitted only in ALK- or ROS1-rearranged NSCLC patients presenting with CNS-only progression. Other ALK inhibitors are prohibited.
6. At least 2 weeks or 5 half-lives, whichever is shorter, must have elapsed after prior chemotherapy or small molecule targeted therapy
7. At least 4 weeks must have elapsed since completion of antibody-directed therapy
8. Prior radiotherapy is allowed if more than 14 days have elapsed since the end of treatment
9. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 and minimum life expectancy of 4 weeks
10. Adequate organ function as defined per protocol
11. Ability to swallow entrectinib intact
12. Other protocol specified criteria

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (120 Sites)

Showing the first 25 of 120 sites.

• Dignity Health St Joseph's Hospital and Medical Center — Phoenix, Arizona
• Mayo Clinic — Phoenix, Arizona
• City of Hope Cancer Center — Duarte, California
• City of Hope Duarte - Comprehensive Cancer Center, Investigational Drug Services — Duarte, California
• Scripps Clinic — La Jolla, California
• University of California San Diego Moores Cancer Center — La Jolla, California
• Southern California Kaiser Permanente — Los Angeles, California
• Univ Of California Irvine College Of Medicine — Orange, California
• UCSF Mount Zion Medical Ctr — San Francisco, California
• UCSF Mission Bay — San Francisco, California
• Sarcoma Oncology Center — Santa Monica, California
• Sarcoma Oncology Research Center LLC — Santa Monica, California
• University of Colorado Cancer Center — Aurora, Colorado
• Yale University — New Haven, Connecticut
• Georgetown University Medical Center Lombardi Cancer Center — Washington D.C., District of Columbia
• Florida Cancer Specialists - Sarasota — Sarasota, Florida
• H. Lee Moffitt Cancer Center and Research Inst. — Tampa, Florida
• Moffitt Cancer Center — Tampa, Florida
• University Cancer & Blood Center, LLC — Athens, Georgia
• Winship Cancer Institute — Atlanta, Georgia
• Southeastern Regional Medical Center, Inc. — Newnan, Georgia
• Northwestern University — Chicago, Illinois
• Advocate Medical Group - Park Ridge, Luther Lane - Oncology — Park Ridge, Illinois
• Midwestern Regional Medical Center — Zion, Illinois
• Weinberg Cancer Institution at Franklin Square — Baltimore, Maryland

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Breast Cancer

• S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer — Anniston, Alabama
• Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer — Columbia, Maryland
• [177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer — Los Angeles, California
• Evaluation And Risk Assessment For Persistent Postsurgical Pain After Breast Surgery — Durham, North Carolina
• TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B) — Palo Alto, California
• A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer — Los Angeles, California

Explore by condition: All Breast Cancer clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.